Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects
Nuvalent Inc. (NASDAQ:NUVL) is one of the best 52-week high stocks to buy right now. On November 24, Truist Securities initiated coverage of Nuvalent Inc.
Nuvalent Inc. (NUVL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 17,248,450 | $1,735,021,586 | -5% | 22.16% |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 5,269,433 | $530,052,265 | 13.53% | |
| 3. | RA Capital Management Peter Kolchinsky | 1,880,057 | $189,114,934 | +51% | 1.94% |
| 4. | Perceptive Advisors Joseph Edelman | 1,665,105 | $167,492,912 | +7% | 2.99% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,536,859 | $154,592,647 | +51% | 0.6% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.50 | 650,000 | $21,775,000.00 | 650,000 | 2022-11-03 | Filing | |
| $33.50 | 149,253 | $4,999,975.50 | 3,577,267 | 2022-11-03 | Filing | |
| $17.00 | 735,000 | $12,495,000.00 | 3,428,014 | 2021-08-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $105.60 | 100 | $10,560.00 | 324,879 | 2026-04-06 | Filing | |
| $104.78 | 6,121 | $641,358.38 | 324,979 | 2026-04-06 | Filing | |
| $103.78 | 12,425 | $1,289,466.50 | 331,100 | 2026-04-06 | Filing | |
| $103.21 | 11,354 | $1,171,846.34 | 343,525 | 2026-04-06 | Filing | |
| $106.18 | 2,469 | $262,158.42 | 85,533 | 2026-04-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,009 | $106,591 | 0% | |
| 2. | 604 | $61,880 | 0% | |
| 3. | 508 | $52,045 | 0% | |
| 4. | 382 | $39,136 | 0% | |
| 5. | 145 | $14,855 | 0.01% |
News See All
12 Best 52-Week High Stocks to Buy Right Now
All three major US indices are poised to end the year near record highs in what is turning out to be a blockbuster year for stocks.
Piper Sandler Initiates Nuvalent (NUVL) Amid Key Cancer Drug Catalysts
Nuvalent, Inc. (NASDAQ:NUVL) ranks among the best mid-cap stocks with huge upside potential. On August 19, Piper Sandler began coverage of Nuvalent, Inc.
12 Best Mid-Cap Stocks with Huge Upside Potential
The Commerce Department said on August 29 that core inflation, which does not include food and energy expenses, stood at a 2.9% seasonally adjusted annual rate based on the personal consumption expenditures...
Nuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLC
Nuvalent Inc. (NASDAQ:NUVL) is one of the best mid cap pharma stocks to buy.
10 Best Mid Cap Pharma Stocks to Buy
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports.
Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer
Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential.
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year. Yoder confirmed her continued...
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
11 Best Guru Stocks to Buy According to Wall Street Analysts
Wall Street seems to be breathing a little easier after the initial panic over President Trump’s tariffs earlier this month, but the rollercoaster is not over just yet.
Hedge Fund Resource Center